Included with registration (non-cme events).

INDUSTRY SYMPOSIA

Tuesday, March 2, 1:00-2:00pm (non-CME)

Assessing the risk of Acute Kidney Injury (AKI)- A paradigm shift in renal care
V. Seenu Reddy, MD, MBA, FACS, FACC
Description:
Acute Kidney Injury (AKI) is one of the more prevalent and serious morbidities in hospitalized patients and is associated with a multitude of acute and chronic conditions. The economic and public health burden of AKI is significant with substantially increased mortality, morbidity, length of ICU stay and in-hospital costs. The NEPHROCHECK® Test [TIMP-2 • IGFBP-7] is an FDA cleared combination biomarker test that can significantly discriminate AKI from no-AKI, and when used in conjunction with clinical evaluation, can aid physicians in optimizing patient management.

Live Questions and Answers


Wednesday, March 3, 1:00-2:00pm (non-CME)

Citrate utilization in CRRT and the impact of RegioCit Replacement Solution
Ashita Tolwani, MD
Topics:
Review COVID-19 and the impact of AKI
Anticoagulation in COVID-19
Key differences with Citrate and Heparin
Citrate use with CRRT in the era of COVID-19
Experiences with Regiocit Replacement Solution

Live Questions and Answers


Thursday, March 4, 1:00-2:00pm (non-CME)

Strategies to limit hypophosphatemia in critically ill patients on CRRT
Javier Neyra, MD and Melissa Thompson-Bastin
Topics:
Phosphate homeostasis during critical illness
Incidence and impact of hypophosphatemia during CRRT
Reactive approaches to manage hypophosphatemia during CRRT –> sliding scales
Preemptive approaches by using phosphate-containing solutions (compounded vs. readily available -Phoxillum)

Live Questions and Answers